FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance
For many years, disappointing results have been generated by many investigations, which have utilized a variety of immunologic strategies to enhance the ability of a patient’s immune system to recognize and eliminate malignant cells. However, in recent years, immunotherapy has been used successfully...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.00457/full |
id |
doaj-1d258a6762934cae8ffb083a304d583f |
---|---|
record_format |
Article |
spelling |
doaj-1d258a6762934cae8ffb083a304d583f2020-11-25T00:00:26ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-04-01810.3389/fimmu.2017.00457258698FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical RelevanceGiuseppe Sconocchia0Sara Caratelli1Tommaso Sconocchia2Roberto Arriga3Andrea Coppola4Giulia Lanzilli5Davide Lauro6Adriano Venditti7Maria Ilaria Del Principe8Francesco Buccisano9Luca Maurillo10Soldano Ferrone11Institute of Translational Pharmacology, CNR, Rome, ItalyInstitute of Translational Pharmacology, CNR, Rome, ItalyInstitute of Translational Pharmacology, CNR, Rome, ItalyDepartment of Systems Medicine, University of Rome “Tor Vergata”, Rome, ItalyDepartment of Systems Medicine, University of Rome “Tor Vergata”, Rome, ItalyInstitute of Translational Pharmacology, CNR, Rome, ItalyDepartment of Systems Medicine, University of Rome “Tor Vergata”, Rome, ItalyDepartment of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, ItalyDepartment of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, ItalyDepartment of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, ItalyDepartment of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, ItalyDepartments of Surgery and of Orthopedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USAFor many years, disappointing results have been generated by many investigations, which have utilized a variety of immunologic strategies to enhance the ability of a patient’s immune system to recognize and eliminate malignant cells. However, in recent years, immunotherapy has been used successfully for the treatment of hematologic and solid malignancies. The impressive clinical responses observed in many types of cancer have convinced even the most skeptical clinical oncologists that a patient’s immune system can recognize and reject his tumor if appropriate strategies are implemented. The success immunotherapy is due to the development of at least three therapeutic strategies. They include tumor-associated antigen (TAA)-specific monoclonal antibodies (mAbs), T cell checkpoint blockade, and TAA-specific chimeric antigen receptors (CARs) T cell-based immunotherapy. However, the full realization of the therapeutic potential of these approaches requires the development of strategies to counteract and overcome some limitations. They include off-target toxicity and mechanisms of cancer immune evasion, which obstacle the successful clinical application of mAbs and CAR T cell-based immunotherapies. Thus, we and others have developed the Fc gamma chimeric receptors (Fcγ-CRs)-based strategy. Like CARs, Fcγ-CRs are composed of an intracellular tail resulting from the fusion of a co-stimulatory molecule with the T cell receptor ζ chain. In contrast, the extracellular CAR single-chain variable fragment (scFv), which recognizes the targeted TAA, has been replaced with the extracellular portion of the FcγRIIIA (CD16). Fcγ-CR T cells have a few intriguing features. First, given in combination with mAbs, Fcγ-CR T cells mediate anticancer activity in vitro and in vivo by an antibody-mediated cellular cytotoxicity mechanism. Second, CD16-CR T cells can target multiple cancer types provided that TAA-specific mAbs with the appropriate specificity are available. Third, the off-target effect of CD16-CR T cells may be controlled by withdrawing the mAb administration. The goal of this manuscript was threefold. First, we review the current state-of-the-art of preclinical CD16-CR T cell technology. Second, we describe its in vitro and in vivo antitumor activity. Finally, we compare the advantages and limitations of the CD16-CR T cell technology with those of CAR T cell methodology.http://journal.frontiersin.org/article/10.3389/fimmu.2017.00457/fullantitumor activitychimeric antigen receptor T cellsCD16-CR T cellsCRCFc gamma chimeric receptorhematologic malignancies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Giuseppe Sconocchia Sara Caratelli Tommaso Sconocchia Roberto Arriga Andrea Coppola Giulia Lanzilli Davide Lauro Adriano Venditti Maria Ilaria Del Principe Francesco Buccisano Luca Maurillo Soldano Ferrone |
spellingShingle |
Giuseppe Sconocchia Sara Caratelli Tommaso Sconocchia Roberto Arriga Andrea Coppola Giulia Lanzilli Davide Lauro Adriano Venditti Maria Ilaria Del Principe Francesco Buccisano Luca Maurillo Soldano Ferrone FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance Frontiers in Immunology antitumor activity chimeric antigen receptor T cells CD16-CR T cells CRC Fc gamma chimeric receptor hematologic malignancies |
author_facet |
Giuseppe Sconocchia Sara Caratelli Tommaso Sconocchia Roberto Arriga Andrea Coppola Giulia Lanzilli Davide Lauro Adriano Venditti Maria Ilaria Del Principe Francesco Buccisano Luca Maurillo Soldano Ferrone |
author_sort |
Giuseppe Sconocchia |
title |
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance |
title_short |
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance |
title_full |
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance |
title_fullStr |
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance |
title_full_unstemmed |
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance |
title_sort |
fcγ chimeric receptor-engineered t cells: methodology, advantages, limitations, and clinical relevance |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2017-04-01 |
description |
For many years, disappointing results have been generated by many investigations, which have utilized a variety of immunologic strategies to enhance the ability of a patient’s immune system to recognize and eliminate malignant cells. However, in recent years, immunotherapy has been used successfully for the treatment of hematologic and solid malignancies. The impressive clinical responses observed in many types of cancer have convinced even the most skeptical clinical oncologists that a patient’s immune system can recognize and reject his tumor if appropriate strategies are implemented. The success immunotherapy is due to the development of at least three therapeutic strategies. They include tumor-associated antigen (TAA)-specific monoclonal antibodies (mAbs), T cell checkpoint blockade, and TAA-specific chimeric antigen receptors (CARs) T cell-based immunotherapy. However, the full realization of the therapeutic potential of these approaches requires the development of strategies to counteract and overcome some limitations. They include off-target toxicity and mechanisms of cancer immune evasion, which obstacle the successful clinical application of mAbs and CAR T cell-based immunotherapies. Thus, we and others have developed the Fc gamma chimeric receptors (Fcγ-CRs)-based strategy. Like CARs, Fcγ-CRs are composed of an intracellular tail resulting from the fusion of a co-stimulatory molecule with the T cell receptor ζ chain. In contrast, the extracellular CAR single-chain variable fragment (scFv), which recognizes the targeted TAA, has been replaced with the extracellular portion of the FcγRIIIA (CD16). Fcγ-CR T cells have a few intriguing features. First, given in combination with mAbs, Fcγ-CR T cells mediate anticancer activity in vitro and in vivo by an antibody-mediated cellular cytotoxicity mechanism. Second, CD16-CR T cells can target multiple cancer types provided that TAA-specific mAbs with the appropriate specificity are available. Third, the off-target effect of CD16-CR T cells may be controlled by withdrawing the mAb administration. The goal of this manuscript was threefold. First, we review the current state-of-the-art of preclinical CD16-CR T cell technology. Second, we describe its in vitro and in vivo antitumor activity. Finally, we compare the advantages and limitations of the CD16-CR T cell technology with those of CAR T cell methodology. |
topic |
antitumor activity chimeric antigen receptor T cells CD16-CR T cells CRC Fc gamma chimeric receptor hematologic malignancies |
url |
http://journal.frontiersin.org/article/10.3389/fimmu.2017.00457/full |
work_keys_str_mv |
AT giuseppesconocchia fcgchimericreceptorengineeredtcellsmethodologyadvantageslimitationsandclinicalrelevance AT saracaratelli fcgchimericreceptorengineeredtcellsmethodologyadvantageslimitationsandclinicalrelevance AT tommasosconocchia fcgchimericreceptorengineeredtcellsmethodologyadvantageslimitationsandclinicalrelevance AT robertoarriga fcgchimericreceptorengineeredtcellsmethodologyadvantageslimitationsandclinicalrelevance AT andreacoppola fcgchimericreceptorengineeredtcellsmethodologyadvantageslimitationsandclinicalrelevance AT giulialanzilli fcgchimericreceptorengineeredtcellsmethodologyadvantageslimitationsandclinicalrelevance AT davidelauro fcgchimericreceptorengineeredtcellsmethodologyadvantageslimitationsandclinicalrelevance AT adrianovenditti fcgchimericreceptorengineeredtcellsmethodologyadvantageslimitationsandclinicalrelevance AT mariailariadelprincipe fcgchimericreceptorengineeredtcellsmethodologyadvantageslimitationsandclinicalrelevance AT francescobuccisano fcgchimericreceptorengineeredtcellsmethodologyadvantageslimitationsandclinicalrelevance AT lucamaurillo fcgchimericreceptorengineeredtcellsmethodologyadvantageslimitationsandclinicalrelevance AT soldanoferrone fcgchimericreceptorengineeredtcellsmethodologyadvantageslimitationsandclinicalrelevance |
_version_ |
1725445202905137152 |